← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $625B	1,977	+3	+0.2%	$198B
2	2 Pfizer PFE $170B	1,747	-34	-2%	$133B
3	3 Merck MRK $370B	1,621	+18	+1%	$126B
4	4 AbbVie ABBV $510B	1,457	+35	+2%	$63.8B
5	5 Bristol-Myers Squibb BMY $126B	1,303	-26	-2%	$57.5B
6	6 Gilead Sciences GILD $196B	1,264	+76	+6%	$115B
7	7 Amgen AMGN $238B	1,186	+4	+0.3%	$72.6B
8	8 Novartis NVS $287B	848	+17	+2%	$21.5B
9	9 GSK GSK $99.4B	723	+10	+1%	$15.1B
10	10 Regeneron Pharmaceuticals REGN $82.5B	448	-5	-1%	$21B
11	11 AstraZeneca AZN $261B	419	+31	+8%	$7.42B
12	12 Jazz Pharmaceuticals JAZZ $14B	305	-13	-4%	$7.51B
13	13 Myriad Genetics MYGN $411M	284	+3	+1%	$4.01B
14	14 Incyte INCY $23.4B	219	-34	-13%	$9.15B
15	SGEN 15 DELISTED Seagen Inc. Common Stock SGEN	197	-13	-6%	$4.89B
16	16 Opko Health OPK $1.25B	175	+7	+4%	$735M
17	17 DELISTED Exact Sciences EXAS	156	+5	+3%	$1.36B
18	CLVS 18 DELISTED Clovis Oncology, Inc. CLVS	140	+3	+2%	$1.16B
19	19 Puma Biotechnology PBYI $551M	138	0	0%	$1.69B
20	20 DELISTED Immunogen Inc IMGN	137	-5	-4%	$887M
21	21 Exelixis EXEL $15.4B	136	-16	-11%	$506M
22	22 DELISTED Assertio ASRT	130	+7	+6%	$627M
23	23 Geron GERN $797M	128	-5	-4%	$245M
24	24 Halozyme HALO $13.7B	128	-3	-2%	$857M
25	SPPI 25 DELISTED Spectrum Pharmaceuticals Inc SPPI	126	+7	+6%	$349M